Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice

Behavioural Brain Research

Volumn 233, Issue 1, 2012, Pages 169-175

  Baldo, Guilherme ^a,b   Mayer, Fabiana Quoos ^a,c   Martinelli, Barbara ^a   Dilda, Anna ^a   Meyer, Fabiola ^a   Ponder, Katherine P ^d   Giugliani, Roberto ^a,b,c   Matte, Ursula ^a,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Post Graduation Program in Biological Sciences: Biochemistry UFRGS   (Brazil)

^c Post Graduation Program in Genetics and Molecular Biology UFRGS   (Brazil)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gait; Hang wire; Mucopolysaccharidosis type I; Neuroinflammation; Open field

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOSAMINOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CEREBELLUM; CONTROLLED STUDY; GAIT; HINDLIMB; HURLER SYNDROME; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NICK END LABELING; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PURKINJE CELL; TASK PERFORMANCE;

AGE FACTORS; AGE OF ONSET; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GAIT; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOSAMINOGLYCANS; HAND STRENGTH; IDURONIDASE; IN SITU NICK-END LABELING; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOVEMENT DISORDERS; MUCOPOLYSACCHARIDOSIS I;

EID: 84861534017     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.04.051     Document Type: Article

References (26)

1. Jardim L.B., Villanueva M.M., de Souza C.F., Netto C.B. Clinical aspects of neuropathic lysosomal storage disorders. Journal of Inherited Metabolic Disease 2010, 33:315-329.
2. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:1902-1907.
3. Ma X., Tittiger M., Knutsen R.H., Kovacs A., Schaller L., Mecham R.P., et al. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Molecular Genetics and Metabolism 2008, 94:298-304.
4. Metcalf J.A., Ma X., Linders B., Wu S., Schambach A., Ohlemiller K.K., et al. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Molecular Therapy 2010, 18:334-342.
5. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., et al. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-l-iduronidase gene. Human Molecular Genetics 1997, 6(4):503-511.
6. Reolon G.K., Braga L.M., Camassola M., Luft T., Henriques J.A., Nardi N.B., et al. Long-term memory for aversive training is impaired in Idua(-/-) mice, a genetic model of mucopolysaccharidosis type I. Brain Research 2006, 1076:225-230.
7. Hartung S.D., Frandsen J.L., Pan D., Koniar B.L., Graupman P., Gunther R., et al. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-l-iduronidase gene. Molecular Therapy 2004, 9(6):866-875.
8. Pan D., Sciascia A., Vorhees C.V., Williams M.T. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Research 2008, 1188:241-253.
9. Wolf D.A., Lenander A.W., Nan Z., Belur L.R., Whitley C.B., Gupta P., et al. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiology of Disease 2011, 43(July (1)):123-133.
10. Garcia-Rivera M.F., Colvin-Wanshura L.E., Nelson M.S., Nan Z., Khan S.A., Rogers T.B., et al. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Research Bulletin 2007, 74:429-438.
11. Reolon G.K., Reinke A., de Oliveira M.R., Braga L.M., Camassola M., Andrades M.E., et al. Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice. Cellular and Molecular Neurobiology 2009, 29:443-448.
12. Baldo G., Matte U., Artigalas O., Schwartz I.V., Burin M.G., Ribeiro E., et al. Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI. Molecular Genetics and Metabolism 2011, 103:197-198.
13. Mauro L.S., Mauro V.F., Miller P.C., Lacher D.A. Effect of cefotetan on creatinine determination by the picric acid and enzymatic methods. Clinical Pharmacy 1989, 8(July (7)):505-508.
14. Roni M.A., Rahman S. Neuronal nicotinic receptor antagonist reduces anxiety-like behavior in mice. Neuroscience Letters 2011, 504:237-241.
15. Hemsley K., Hopwood J.J. Development of motor deficits in a murine model of mucopolyssaccharidosis type IIIA. Behavioural Brain Research 2005, 158:191-199.
16. 2+ channel mutant. Neurobiology of Aging 2008, 29:1733-1743.
17. Takahashi E., Niimi K., Itakura C. Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2. 1 mutant mice. Brain Research 2009, 1279:50-57.
18. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Molecular Genetics and Metabolism 2007, 90:171-180.
19. Wolf DA, Lenander AW, Nan Z, Braunlin EA, Podetz-Pedersen KM, Whitley CB, et al. Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I. Bone Marrow Transplantation, in press.
20. Lau A.A., Crawley A.C., Hopwood J.J., Hemsley K.M. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behavioural Brain Research 2008, 191(1):130-136.
21. Langford-Smith A., Malinowska M., Langford-Smith K.J., Wegrzyn G., Jones S., Wynn R., et al. Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments. Genes, Brain, and Behavior 2011, 10:673-682.
22. Wegrzyn G., Jakóbkiewicz-Banecka J., Narajczyk M., WiŚniewski A., Piotrowska E., Gabig-Cimińska M., et al. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?. Medical Hypotheses 2010, 75:605-609.
23. Chung S., Ma X., Liu Y., Lee D., Tittiger M., Ponder K.P. Effect of neonatal administration of a retroviral vector expressing alpha-l-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Molecular Genetics and Metabolism 2007, 90:181-192.
24. Wynne A.M., Henry C.J., Godbout J.P. Immune and behavioral consequences of microglial reactivity in the aged brain. Integrative & Comparative Biology 2009, 49:254-266.
25. Arfi A., Richard M., Gandolphe C., Bonnefont-Rousselot D., Thérond P., Scherman D. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Molecular Genetics and Metabolism 2011, 103:18-25.
26. Russell C., Hendson G., Jevon G., Matlock T., Yu J., Aklujkar M., et al. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clinical Genetics 1998, 53:349-361.